With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. The latest readout positions Breyanzi for a ...

As the major cost-cutting initiative at Bristol Myers Squibb rolls on, the company has launched another round of layoffs in its home state of New Jersey. BMS’ latest workforce reduction affects ...

Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $65.00. The company’s shares closed yesterday at $57.42.

Bristol-Myers Squibb (BMY) shares are under pressure after the company provided soft guidance due to competition among generic drugmakers. Peloton (PTON) stock jumps after beating on earnings and ...

Bristol Myers Squibb posted Q4 revenue of $12.34B, beating the consensus, with an 8% YoY increase driven by Growth Portfolio and Eliquis. Adjusted EPS was $1.67, topping the $1.46 consensus but ...

Pharma giant Bristol Myers Squibb is planning another round of cost cutting as part of a broader restructuring plan. Under the “strategic productivity initiative” announced Feb. 6, the ...

Shares in Bristol-Myers Squibb traded about 2.7% lower Thursday after the drug maker gave 2025 guidance that undershot expectations. Bristol expects sales of about $45.5 billion in 2025 ...

Dividend Commitment: 2025 marks the 93rd consecutive year of dividend payments. Bristol-Myers Squibb Co (NYSE:BMY) achieved double-digit revenue growth in 2024, driven by key products like ...

Bristol Myers Squibb said it has received positive results for its latest lymphoma treatment trials, the fifth type of cancer the drug has been shown to treat. The biopharmaceutical company said ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and broad Medicaid/Medicare coverage, supporting its blockbuster potential in schizophrenia and future label expansions.

(RTTNews) - While reporting financial results for the fourth quarter on Thursday, Bristol-Myers Squibb Co. (BMY) initiated its adjusted earnings and revenue growth guidance for the full-year 2025.

Welcome to the Bristol-Myers Squibb Fourth Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an ...